AnPac Bio-Medical Science Co Operating Income

AnPac Bio-Medical Science Co's operating income stands at $-100M as of December 2022. That compares with $-110M in the prior-year period — up 6.5% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

AnPac Bio-Medical Science Co reported $-100M in operating income versus $-110M a year earlier — a 6.5% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $-110M in the prior-year period — up 6.5% year over year. Sustained growth in operating income can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how AnPac Bio-Medical Science Co's operating income evolved across reporting periods, while the comparison chart places ANPC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, operating income is commonly used to spot outliers. AnPac Bio-Medical Science Co's reading of $-100M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.